Health and Healthcare
New Ebola Fears in NYC Make Major Ebola Stock Waves (Updated)
Published:
Last Updated:
Just when you thought the Ebola virus outbreak risk was dwindling down… Fresh headlines from Dow Jones and the New York post have put the markets on Ebola watch all over again. The location could not be worse — New York City. A doctor who had treated Ebola patients in western Africa has reportedly been taken to Bellevue Hospital and has been quarantined.
New York City is the worst of all places that an Ebola case could be diagnosed. The city has the a massive population density, which is likely one of the most densely populated cities in the world. CNBC ran a statement from Bellevue hospital signaling that the patient is being tested and has not yet been diagnosed.
As of 3:20 p.m. Eastern Time, the Dow Jones industrial Average was up 220 points after having been up 300 points prior to the potential Ebola news. It goes without saying, but the Ebola stocks and those which do poorly against Ebola have made significant moves.
PLEASE NOTE: This story has been updated for price action.
Lakeland Industries Inc. (NASDAQ: LAKE) was up about 13% at $14.80, against a 52-week range of $4.75 to $29.55. Lakeland makes many of the hazmat suits, and it specifically now has suits designed for Ebola treatment. Update 3:33: shares up 18% at $15.50 on 4.3 million shares.
Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR) was up almost 4% at $19.98, against a 52-week range of $7.17 to $31.48. Volume was thin. Update 3:34 shares up 2.7% at $19.80 on 2.07 million shares.
Chimerix Inc. (NASDAQ: CMRX) was down almost over 5% at $32.22, against a 52-week range of $12.96 to $36.75. Trading volume was light. Update 3:34 shares up 4.7% at $32.05 on 740,000 shares.
Sarepta Therapeutics Inc. (NASDAQ: SRPT) was up around 3% at $23.00, against a 52-week range of $12.12 to $44.29. Update 3:34 shares up 3.7% at $23.12 on 910,000 shares.
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) was up 4% at $12.20, against a 52-week range of $4.55 to $14.62. Update 3:35 shares up 4.7% at $12.25 on 1.03 million shares.
iBio Inc. (NYSEMKT: IBIO), which has proprietary plant-based protein expression technologies to speed up vaccine development, was down 10% at $1.59 with over 18 million shares moving on the day, against a 52-week range of $0.24 to $3.48. Update 3:36 shares were down 0.5% at $1.76 on 21.5 million shares but this stock was as low as $1.29 earlier in the day.
Allied Healthcare Products Inc. (NASDAQ: AHPI) was down up 5% at $2.19, but on thin trading volume. Its 52-week range is $1.60 to $3.90. Allied makes respiratory systems for inside of suits. Update 3:37 shares up 4% at $2.17 on almost 200,000 shares.
ALSO READ: States With the Best Quality of Life
Alpha Pro Tech Ltd. (NYSEMKT: APT) was up 7% at $4.60, against a 52-week range of $1.50 to $10.73. Alpha Pro is also in disposable protective apparel and is a hazmat protection company. Update 3:38 shares up 5.3% at $4.53 on 8.8 million shares.
Versar Inc. (NYSE: VSR) was down over 8% at $3.55, against a 52-week range of $2.69 to $7.84. It is a technical project management company. Update 3:38 shares up 6.4% at $3.48 on 3.3 million shares.
Cerus Corp. (NASDAQ: CERS) was trading down 1% at $4.06 against a 52-week range of $3.48 to $8.00. Update 3:38 shares down 1.1% at $4.06 on 701,000 shares — stock has been unresponsive.
JetBlue Airways Corp. (NASDAQ: JBLU) was down almost 4% at $10.74, and its 52-week trading range is $7.05 to $12.83. We have only covered JetBlue out of all the airlines stocks because most of its flights come in and out of New York. Update 3:40 shares still down 3.6% at $10.78 — hardly changed at all as focus not on airlines after their earnings.
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.